Also known as Namenda
Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA-type glutamate receptors. It was first synthesized by Eli Lilly and Company in 1968. Memantine is marketed under the brands Axura and Akatinol by Merz, Namenda by Forest, Ebixa and Abixa by Lundbeck and Memox by Unipharm. Memantine has been shown to have a modest effect in moderate-to-severe Alzheimer's disease and in dementia with Lewy bodies. Despite years of research, there is little evidence of effect in mild Alzheimer's disease.Source: Wikipedia
Estimated Total Cost: $156.75 for an average of 28 days supply
Patients are most commonly prescribed memantine to treat alzheimer disease, disturbance of memory, delirium, and dementia.
Patients taking memantine most commonly experience side effects like headache, diarrhea, and constipation.